Latest data from the Hong Kong Stock Exchange reveals that on December 24, a shareholder of Innovent Biologics (01801) deposited shares with HSBC Hong Kong, with a custody market value of HK$4.598 billion, representing 3.31% of the company's shares. UBS issued a research report stating that six new products from Innovent Biologics, along with new indications for sintilimab, have been included in the latest edition of the National Reimbursement Drug List (2025). Additionally, Innovent Biologics has been officially added to the Hang Seng Index. UBS maintains a "Buy" rating on the stock with a target price of HK$137.4.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments